SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (1502)10/23/1998 3:18:00 PM
From: Rudy Saucillo  Read Replies (3) | Respond to of 2173
 
The data we've seen from the PhII trials and the 4 PhIII trials to date clearly show that pimagidine is a failure as a potential therapeutic. Yes, the clinical program was at the very least poorly planned. Investors should not have had confidence as protocols were modified in an attempt to achieve desired results.

It remains to be seen if Amylin can survive as a corporate entity. Finances are the big issue and there are none (not withstanding Murphy's bs about a new corporate partner any minute now!). Given the latest PhIII results, there's no reason to continue with the ongoing trials. Better for the company, investors, and the industry in general if Amylin quickly shuts down their pimagidine program.

Rudy



To: David Bogdanoff who wrote (1502)10/23/1998 10:17:00 PM
From: arnie h  Respond to of 2173
 
David: Thanks for your perspective on this. Based on the positive glimpses, it does seem there is something to the amylin story. Ordinarily, one would think just the science involving glucose, weight and cholesterol control would be worth something. At today's stock price, that is less than $10M. In today's R&D world, it would be hard to get anything for that cost. Perhaps, the strict focus on one disease has minimised scientific value.

Arnie


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News